Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Family Office Focuses On New Treatments For Eye Diseases and Cancer

21 Mar

A family office based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to PhI stages, and will generally invest $5-10M in series A rounds. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, the firm is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Finance Firm Invests in Clinical-Stage Therapeutics and Diagnostics

21 Mar

A Corporate Finance firm focused on venture and private equity investments supports SMEs across Europe with attention to Austria. The company has built a track record of creating significant value as investors by developing deep industry expertise in sectors including renewable energy, high-tech and bio-tech.

The firm is interested in companies in the therapeutics and diagnostics space in particular and is open to considering medical device companies as well. The firm is open to any indication and sub-sector but requires that the firm’s asset be ready to enter a Phase I study in order to be considered.

The firm is looking for private companies with exceptional management teams in place. The firm often looks to take a board seat and provide a lot more than just financial aid to companies they invest in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Raises New Fund For Platform Technologies

21 Mar

A venture capital firm based Switzerland raised a new fund in 2019.  The firm generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 5 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe, with a core focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, medtech etc.. The firm focuses on companies developing biotech platforms, research tools and digital health startups. The firm will not invest in pure drug development companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, antibody development platforms and a technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: